



PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/735,973
	Filing Date	December 15, 2003
	First Named Inventor	Certa, et al.
	Art Unit	
	Examiner Name	
Total Number of Pages in This Submission	Attorney Docket Number	21507 US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks -References B1 to B5, and C1 to C17; and -PTO-1449 Form	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name	Kimberly J. Prior	
Signature		
Date	3/15/2004	

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.		
Typed or printed name	Kimberly J. Prior	
Signature		Date 3/15/2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventors: Certa, et al.

Serial No. 10/735,973, filed December 15, 2003
(Ref. No. 21507 US)

For: **MODIFIED PHOSPHODIESTERASE POLYPEPTIDES WITH ALTERED
PHYSIOCHEMICAL PROPERTIES**

INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110
March 15, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.


Documents B1 to B5, and C1 to C17 listed on Form PTO-1449 are enclosed.

Consideration of all the documents cited on Form PTO-1449 is requested.

Serial No. 10/735,973
Filed: December 15, 2003

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Kimberly J. Prior", is written over a horizontal line.

Attorney for Applicant(s)
Kimberly J. Prior
(Reg. No. 41,483)
340 Kingsland Street
Nutley, New Jersey 07110
Telephone: (973) 235-6208
Telefax: (973) 235-2363

139946

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/735,973
Filing Date	December 15, 2003
First Name Inventor	Certa et al.
Attorney Docket Number	21507 US

U.S. PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	A				

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)		
	B1	WO	02/074992		09/26/2002	
	B2	WO	00/09504		02/24/2000	
	B3	WO	01/35979		05/25/2001	
	B4	WO	01/68600		09/20/2001	
	B5	WO	98/45268		10/15/1998	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	C1	Beard, M. B. et al., Cellular Signalling Vol. 14 (2002) pgs. 453-465	
	C2	Beavo et al., Molecular Pharmacology Vol. 46, pgs. 399-405 (1994)	
	C3	Perry & Higgs, Curr. Opinion Chem. Biol. Vol. 2 pgs. 472-481 (1998)	
	C4	Houslay & Milligan, Trends in Biochem. Sci. Vol. 22 pgs. 217-224 (1997)	
	C5	Beavo & Reifsnnyder, Trends Pharmacol. Sci. Vol. 11, pgs. 150-155 (1990)	
	C6	Bolger et al., Mol. Cell. Biol. Vol. 13 pgs. 6558-6571 (1993)	
	C7	Houslay, Sullivan & Bolger, Adv. Pharmacol. Vol. 44, pgs. 225-245 (1998)	
	C8	McPhee et al. Biochem. J. Vol. 310, pgs. 965-974 (1995)	
	C9	Hughes et al. Drug Discov. Today, Vol. 2, pgs. 89-101 (1997)	
	C10	Torphy, Am. J. Respir. Crit. Care Med. Vol. 157, pgs. 351-370 (1998)	
	C11	Teixeira et al. Trends Pharm. Sci. pgs. 164-171 (1997)	
	C12	Entman & Smith, Cardiovasc. Res. Vol. 28, pgs. 1301-1311 (1994)	
	C13	Bowie, Science Vol. 247 (1990) pgs. 1306-1310	
	C14	Fritz & Anderson, Methods in Enzymology (2000) Vol. 327, pgs. 3-16	
	C15	Hopp, T. P. (1988) Biotechnology Vol. 6, pgs. 1204-1210	
	C16	Sisk et al. (1994) J. Virol. Vol. 68, pgs. 766-775	
	C17	Owens, et al. Biochem. J. (1997) 326; 53-60	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.